SAN DIEGO—TearLab, an eyecare medical device firm marketing lab-on-a-chip diagnostic technologies at the point-of-care, has named Adam Szaronos chief commercial officer. Szaronos brings a wealth of experience gained over the past 15 years and will help guide the evolution of TearLab as it transforms its business model in 2020 and beyond, according to the company’s announcement this week. Szaronos joins the TearLab executive team from Alcon, where he was most recently head of dry eye devices with responsibility for building and leading the company's commercial business unit in the dry eye disease and MGD (meibomian gland dysfunction) space, according to the TearLab announcement.

He brings years of comprehensive eyecare industry and leadership experience, having led commercial teams and new ventures across Alcon's surgical and vision care organizations. Szaronos holds an MBA from Massachusetts Institute of Technology's Sloan School of Management, a certificate in Strategic Marketing Management from Harvard Business School, and a Bachelor of Science from Indiana University's Kelley School of Business.

"I am delighted to welcome Adam to TearLab," said Seph Jensen, chief executive officer of TearLab. "Adam brings with him an energetic, positive spirit that will usher our organization into a new and exciting era. As a proven business leader, combined with his unique skillset, Adam brings the necessary knowledge and experience to build a strong team that will support our vision for TearLab.”

Recently, TearLab was acquired by investment firm Accelmed Partners. Following the acquisition, TearLab transitioned from being a publicly traded company to a privately held company and is positioned to pursue further development of its next-generation Discovery platform.

It is also able to seek out targeted acquisition opportunities supporting a comprehensive portfolio that better addresses dry eye disease market dynamics and patient care needs.